Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma

por Zeissig, Mara N., Zannettino, Andrew C. W., Vandyke, Kate
Publicado 2020

N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer

por Mrozik, Krzysztof Marek, Blaschuk, Orest William, Cheong, Chee Man, Zannettino, Andrew Christopher William, Vandyke, Kate
Publicado 2018

SAMSN1 Is a Tumor Suppressor Gene in Multiple Myeloma()()

por Noll, Jacqueline E., Hewett, Duncan R., Williams, Sharon A., Vandyke, Kate, Kok, Chung, To, Luen B., Zannettino, Andrew C.W.
Publicado 2014

GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice

por Friend, Natasha, Noll, Jacqueline E., Opperman, Khatora S., Clark, Kimberley C., Mrozik, Krzysztof M., Vandyke, Kate, Hewett, Duncan R., Zannettino, Andrew C. W.
Publicado 2020

Characterization of the role of Samsn1 loss in multiple myeloma development

por Friend, Natasha L., Hewett, Duncan R., Panagopoulos, Vasilios, Noll, Jacqueline E., Vandyke, Kate, Mrozik, Krzysztof M., Fitter, Stephen, Zannettino, Andrew C.W.
Publicado 2020

Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo

por Zeissig, Mara N., Hewett, Duncan R., Panagopoulos, Vasilios, Mrozik, Krzysztof M., To, L. Bik, Croucher, Peter I., Zannettino, Andrew C.W., Vandyke, Kate
Publicado 2020

PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma

por Noll, Jacqueline E., Vandyke, Kate, Hewett, Duncan R., Mrozik, Krzysztof M., Bala, Rachel J., Williams, Sharon A., Kok, Chung H., Zannettino, Andrew CW
Publicado 2015

DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment

por Hewett, Duncan R., Vandyke, Kate, Lawrence, David M., Friend, Natasha, Noll, Jacqueline E., Geoghegan, Joel M., Croucher, Peter I., Zannettino, Andrew C.W.
Publicado 2017

LCRF‐0006, a small molecule mimetic of the N‐cadherin antagonist peptide ADH‐1, synergistically increases multiple myeloma response to bortezomib

por Mrozik, Krzysztof M., Cheong, Chee M., Hewett, Duncan R., Noll, Jacqueline E., Opperman, Khatora S., Adwal, Alaknanda, Russell, Darryl L., Blaschuk, Orest W., Vandyke, Kate, Zannettino, Andrew C. W.
Publicado 2020

Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress

por Wallington-Beddoe, Craig T., Bennett, Melissa K., Vandyke, Kate, Davies, Lorena, Zebol, Julia R., Moretti, Paul A.B., Pitman, Melissa R., Hewett, Duncan R., Zannettino, Andrew C.W., Pitson, Stuart M
Publicado 2017

Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo

por Opperman, Khatora S., Vandyke, Kate, Clark, Kimberley C., Coulter, Elizabeth A., Hewett, Duncan R., Mrozik, Krzysztof M., Schwarz, Nisha, Evdokiou, Andreas, Croucher, Peter I, Psaltis, Peter J, Noll, Jacqueline E, Zannettino, Andrew CW
Publicado 2019

Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In Vivo

por Clark, Kimberley C., Hewett, Duncan R., Panagopoulos, Vasilios, Plakhova, Natalya, Opperman, Khatora S., Bradey, Alanah L., Mrozik, Krzysztof M., Vandyke, Kate, Mukherjee, Siddhartha, Davies, Gareth C.G., Worthley, Daniel L., Zannettino, Andrew C.W.
Publicado 2020

Desmoglein‐2 expression is an independent predictor of poor prognosis patients with multiple myeloma

por Ebert, Lisa M., Vandyke, Kate, Johan, M. Zahied, DeNichilo, Mark, Tan, Lih Y., Myo Min, Kay K., Weimann, Benjamin M., Ebert, Brenton W., Pitson, Stuart M., Zannettino, Andrew C. W., Wallington‐Beddoe, Craig T., Bonder, Claudine S.
Publicado 2021